Cardiovascular Research

Aspects of Tryptophan and Nicotinamide Adenine Dinucleotide in Immunity: A New Twist in an Old Tale.

Authors: Hector Rodriguez Cetina Biefer|||Anju Vasudevan|||Abdallah Elkhal

Affiliations: + Expand

Abstract

Increasing evidence underscores the interesting ability of tryptophan to regulate immune responses. However, the exact mechanisms of tryptophan's immune regulation remain to be determined. Tryptophan catabolism via the kynurenine pathway is known to play an important role in tryptophan's involvement in immune responses. Interestingly, quinolinic acid, which is a neurotoxic catabolite of the kynurenine pathway, is the major pathway for the synthesis of nicotinamide adenine dinucleotide (NAD+). Recent studies have shown that NAD+, a natural coenzyme found in all living cells, regulates immune responses and creates homeostasis via a novel signaling pathway. More importantly, the immunoregulatory properties of NAD+ are strongly related to the overexpression of tryptophan hydroxylase 1 (Tph1). This review provides recent knowledge of tryptophan and NAD+ and their specific and intriguing roles in the immune system. Furthermore, it focuses on the mechanisms by which tryptophan regulates NAD+ synthesis as well as innate and adaptive immune responses.

---

Reference List

Hopkins FG, Cole SW. A contribution to the chemistry of proteids: part I. A preliminary study of a hitherto undescribed product of tryptic digestion. J Physiol (Lond) 1901;27:418–428.|||Richard DM, Dawes MA, Mathias CW, Acheson A, Hill-Kapturczak N, Dougherty DM. L-tryptophan: basic metabolic functions, behavioral research and therapeutic indications. Int J Tryptophan Res. 2009;2:45–60.|||Orhan F, Bhat M, Sandberg K, et al. Tryptophan metabolism along the kynurenine pathway downstream of toll-like receptor stimulation in peripheral monocytes. Scand J Immunol. 2016;84:262–271.|||Bender DA. Biochemistry of tryptophan in health and disease. Mol Aspects Med. 1983;6:101–197.|||Blankfield A. A brief historic overview of clinical disorders associated with tryptophan: the relevance to chronic fatigue syndrome (CFS) and fibromyalgia (FM) Int J Tryptophan Res. 2012;5:27–32.|||Lichters M, Brunnlieb C, Nave G. The influence of serotonin deficiency on choice deferral and the compromise effect. J Marketing Res. 2016;53:183–198.|||Rose DP. Aspects of tryptophan metabolism in health and disease: a review. J Clin Pathol. 1972;25:17–25.|||Gracia-Rubio I, Moscoso-Castro M, Pozo OJ, Marcos J, Nadal R, Valverde O. Maternal separation induces neuroinflammation and long-lasting emotional alterations in mice. Prog Neuropsychopharmacol Biol Psychiatry. 2016;65:104–117.|||Adams S, Braidy N, Bessesde A, et al. The kynurenine pathway in brain tumor pathogenesis. Cancer Res. 2012;72:5649–5657.|||Pilotte L, Larrieu P, Stroobant V, et al. Reversal of tumoral immune resistance by inhibition of tryptophan 2,3-dioxygenase. Proc Natl Acad Sci U S A. 2012;109:2497–2502.|||Puccetti P, Fallarino F, Italiano A, et al. Accumulation of an endogenous tryptophan-derived metabolite in colorectal and breast cancers. PLoS ONE. 2015;10:e0122046.|||Popov A, Schultze JL. IDO-expressing regulatory dendritic cells in cancer and chronic infection. J Mol Med. 2008;86:145–160.|||Platten M, Wick W, Van den Eynde BJ. Tryptophan catabolism in cancer: beyond IDO and tryptophan depletion. Cancer Res. 2012;72:5435–5440.|||Lee GK, Park HJ, Macleod M, Chandler P, Munn DH, Mellor AL. Tryptophan deprivation sensitizes activated T-cells to apoptosis prior to cell division. Immunology. 2002;107:452–460.|||Kushwah R, Hu J. Role of dendritic cells in the induction of regulatory T-cells. Cell Biosci. 2010;1:20.|||Maldonado RA, von Andrian UH. How tolerogenic dendritic cells induce regulatory T-cells. Adv Immunol. 2009;108:111–165.|||Moffett JR, Namboodiri MA. Tryptophan and the immune response. Immunol Cell Biol. 2003;81:247–265.|||Wang Q, Liu D, Song P, Zou MH. Tryptophan-kynurenine pathway is dysregulated in inflammation, and immune activation. Front Biosci. 2015;20:1116–1143.|||Pertovaara M, Raitala A, Uusitalo H, et al. Mechanisms dependent on tryptophan catabolism regulate immune responses in primary Sjogren’s syndrome. Clin Exp Immunol. 2005;142:155–161.|||van Baren N, Van den Eynde BJ. Tumoral immune resistance mediated by enzymes that degrade tryptophan. Cancer Immunol Res. 2015;3:978–985.|||Schröcksnadel K, Wirleitner B, Winkler C, Fuchs D. Monitoring tryptophan metabolism in chronic immune activation. Clin Chim Acta. 2006;364:82–90.|||Jones SP, Guillemin G, Brew B. The kynurenine pathway in stem cell biology. Int J Tryptophan Res. 2013;6:57–66.|||Michelhaugh SK, Varadarajan K, Guastella AR, Mittal S. Role of kynurenine pathway in neuro-oncology. In: Mittal S, editor. Targeting the Broadly Pathogenic Kynurenine Pathway. Cham: Springer International Publishing; 2015. pp. 287–295.|||Grant RS, Passey R, Matanovic G, Smythe G, Kapoor V. Evidence for increased de novo synthesis of NAD in immune-activated RAW264.7 macrophages: a self-protective mechanism? Arch Biochem Biophys. 1999;372:1–7.|||Berger SJ, Sudar DC, Berger NA. Metabolic consequences of DNA damage: DNA damage induces alterations in glucose metabolism by activation of poly (ADP-ribose) polymerase. Biochem Biophys Res Commun. 1986;134:227–232.|||Berger F, Ramírez-Hernández MH, Ziegler M. The new life of a centenarian: signalling functions of NAD(P) Trends Biochem Sci. 2004;29:111–118.|||Braidy N, Guillemin GJ, Grant R. Effects of kynurenine pathway inhibition on NAD+ metabolism and cell viability in human primary astrocytes and neurons. Int J Tryptophan Res. 2011;4:29–37.|||Guillemin GJ. Quinolinic acid, the inescapable neurotoxin. FEBS J. 2012;279:1356–1365.|||Tullius SG, Cetina Biefer HR, Li S, et al. NAD+ protects against EAE by regulating CD4+ T-cell differentiation. Nat Commun. 2014;5:5101.|||Elkhal A, Cetina Biefer HR, Heinbokel T, et al. NAD+ regulates Treg cell fate and promotes allograft survival via a systemic IL-10 production that is CD4+ CD25+ Foxp3+ T-cells independent. Sci Rep. 2016;6:22325.|||Wang J, Zhao C, Kong P, et al. Treatment with NAD+ inhibited experimental autoimmune encephalomyelitis by activating AMPK/SIRT1 signaling pathway and modulating Th1/Th17 immune responses in mice. Int Immunopharmacol. 2016;39:287–294.|||Kawasaki H, Chang HW, Tseng HC, et al. A tryptophan metabolite, kynurenine, promotes mast cell activation through aryl hydrocarbon receptor. Allergy. 2014;69:445–452.|||Xie FT, Cao JS, Zhao J, Yu Y, Qi F, Dai XC. IDO expressing dendritic cells suppress allograft rejection of small bowel transplantation in mice by expansion of Foxp3+ regulatory T-cells. Transpl Immunol. 2015;33:69–77.|||Uyttenhove C, Pilotte L, Théate I, et al. Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat Med. 2003;9:1269–1274.|||Yan Y, Zhang G-X, Gran B, et al. IDO upregulates regulatory T-cells via tryptophan catabolite and suppresses encephalitogenic T-cell responses in experimental autoimmune encephalomyelitis. J Immunol. 2010;185:5953–5961.|||Stockinger B, Meglio PD, Gialitakis M, Duarte JH. The aryl hydrocarbon receptor: multitasking in the immune system. Annu Rev Immunol. 2014;32:403–432.|||Quintana FJ, Sherr DH. Aryl hydrocarbon receptor control of adaptive immunity. Pharmacol Rev. 2013;65:1148–1161.|||Quintana FJ. The aryl hydrocarbon receptor: a molecular pathway for the environmental control of the immune response. Immunology. 2013;138:183–189.|||Apetoh L, Quintana FJ, Pot C, et al. The aryl hydrocarbon receptor interacts with c-Maf to promote the differentiation of type 1 regulatory T-cells induced by IL-27. Nat Immunol. 2010;11:854–861.|||Gandhi R, Kumar D, Burns EJ, et al. Activation of the aryl hydrocarbon receptor induces human type 1 regulatory T-cell-like and Foxp3+ regulatory T-cells. Nat Immunol. 2010;11:846–853.|||Quintana FJ, Basso AS, Iglesias AH, et al. Control of T(reg) and T(H)17 cell differentiation by the aryl hydrocarbon receptor. Nature. 2008;453:65–71.|||Rodrigues CP, Ferreira ACF, Pinho MP, de Moraes CJ, Bergami-Santos PC, Barbuto JAM. Tolerogenic IDO(+) dendritic cells are induced by PD-1-expressing mast cells. Front Immunol. 2016;7:9.|||Mellor AL, Munn DH. IDO expression by dendritic cells: tolerance and tryptophan catabolism. Nat Rev Immunol. 2004;4:762–774.|||Engin AB. Evaluation of tryptophan metabolism in chronic immune activation. In: Engin A, Engin AB, editors. Tryptophan Metabolism: Implications for Biological Processes, Health and Disease (Molecular and Integrative Toxicology) Cham, Switzerland: Springer International Publishing; 2015. pp. 121–145.|||Opitz CA, Litzenburger UM, Sahm F, et al. An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor. Nature. 2011;478:197–203.|||Li L, Huang L, Lemos HP, Mautino M, Mellor AL. Altered tryptophan metabolism as a paradigm for good and bad aspects of immune privilege in chronic inflammatory diseases. Front Immunol. 2012;3:109.|||Puccetti P. On the non-redundant roles of TDO2 and IDO1. Front Immunol. 2014;5:522.|||Poulain-Godefroy O, Eury E, Leloire A, et al. Induction of TDO2 and IDO2 in liver by high-fat feeding in mice: discrepancies with human obesity. Int J Tryptophan Res. 2013;6:29–37.|||D’Amato NC, Rogers TJ, Gordon MA, et al. A TDO2-AhR signaling axis facilitates anoikis resistance and metastasis in triple-negative breast cancer. Cancer Res. 2015;75:4651–4664.|||Novikov O, Wang Z, Stanford EA, et al. An aryl hydrocarbon receptor-mediated amplification loop that enforces cell migration in ER-/PR-/Her2- human breast cancer cells. Mol Pharmacol. 2016;90:674–688.|||Hsu Y-L, Hung J-Y, Chiang S-Y, et al. Lung cancer-derived galectin-1 contributes to cancer associated fibroblast-mediated cancer progression and immune suppression through TDO2/kynurenine axis. Oncotarget. 2016;7:27584–27598.|||Crosignani S, Driessens G, Detheux M, Van den Eynde B, Cauwenberghs S. Preclinical assessment of a novel small molecule inhibitor of tryptophan 2,3-di-oxygenase 2 (TDO2) J Immunother Cancer. 2014;2:196.|||Hwang SL, Chung NP-Y, Chan JK-Y, Lin CL. Indoleamine 2,3-dioxygenase (IDO) is essential for dendritic cell activation and chemotactic responsiveness to chemokines. Cell Res. 2005;15:167–175.|||Miwa N, Hayakawa S, Miyazaki S, et al. IDO expression on decidual and peripheral blood dendritic cells and monocytes/macrophages after treatment with CTLA-4 or interferon-gamma increase in normal pregnancy but decrease in spontaneous abortion. Mol Hum Reprod. 2005;11:865–870.|||Takikawa O. Biochemical and medical aspects of the indoleamine 2,3-dioxygenase-initiated L-tryptophan metabolism. Biochem Bioph Res Co. 2005;338:12–19.|||Fujigaki S, Saito K, Takemura M, et al. Species differences in L-tryptophan-kynurenine pathway metabolism: quantification of anthranilic acid and its related enzymes. Arch Biochem Biophys. 1998;358:329–335.|||Werner-Felmayer G, Werner ER, Fuchs D, Hausen A, Reibnegger G, Wachter H. Characteristics of interferon induced tryptophan metabolism in human cells in vitro. Biochim Biophys Acta. 1989;1012:140–147.|||Dai W, Gupta SL. Regulation of indoleamine 2,3-dioxygenase gene expression in human fibroblasts by interferon-gamma. Upstream control region discriminates between interferon-gamma and interferon-alpha. J Biol Chem. 1990;265:19871–19877.|||Hill M, Tanguy Royer S, Royer P, et al. IDO expands human CD4+CD25high regulatory T-cells by promoting maturation of LPS-treated dendritic cells. Eur J Immunol. 2007;37:3054–3062.|||Sioud M, Nyakas M, Sæbøe-Larssen S, Mobergslien A, Aamdal S, Kvalheim G. Diversification of antitumour immunity in a patient with metastatic melanoma treated with ipilimumab and an IDO-silenced dendritic cell vaccine. Case Rep Med. 2016;2016:9639585.|||Zheng X, Koropatnick J, Chen D, et al. Silencing IDO in dendritic cells: a novel approach to enhance cancer immunotherapy in a murine breast cancer model. Int J Cancer. 2013;132:967–977.|||Yamahira A, Narita M, Iwabuchi M, et al. Activation of the leukemia plasmacytoid dendritic cell line PMDC05 by Toho-1, a novel IDO inhibitor. Anticancer Res. 2014;34:4021–4028.|||Wang X-F, Wang H-S, Wang H, et al. The role of indoleamine 2,3-dioxygenase (IDO) in immune tolerance: focus on macrophage polarization of THP-1 cells. Cell Immunol. 2014;289:42–48.|||Prendergast GC, Metz R, Muller AJ. IDO recruits Tregs in melanoma. Cell Cycle. 2009;8:1818–1819.|||Wainwright DA, Dey M, Chang A, Lesniak MS. Targeting Tregs in malignant brain cancer: overcoming IDO. Front Immunol. 2013;4:116.|||Davies NW. Tryptophan, neurodegeneration and HIV-associated neurocognitive disorder. Int J Tryptophan Res. 2010;3:121–140.|||Abel J, Haarmann-Stemmann T. An introduction to the molecular basics of aryl hydrocarbon receptor biology. Biol Chem. 2010;391:1235–1248.|||Mimura J, Yamashita K, Nakamura K, et al. Loss of teratogenic response to 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) in mice lacking the Ah (dioxin) receptor. Genes Cells. 1997;2:645–654.|||Chen X, Oppenheim JJ. Th17 cells and Tregs: unlikely allies. J Leukoc Biol. 2014;95:723–731.|||Pan F, Fan H, Lu L, Liu Z, Jiang S. The yin and yang of signaling in Tregs and TH17 cells. Sci Signal. 2011;4:mr4.|||Kipnis E, Dessein R. Bacterial modulation of Tregs/Th17 in intestinal disease: a balancing act? Inflamm Bowel Dis. 2012;18:1389–1390.|||Swain SL, McKinstry KK, Strutt TM. Expanding roles for CD4+ T-cells in immunity to viruses. Nat Rev Immunol. 2012;12:136–148.|||Jiang S, Dong C. A complex issue on CD4(+) T-cell subsets. Immunol Rev. 2013;252:5–11.|||Loser K, Mehling A, Loeser S, et al. Epidermal RANKL controls regulatory T-cell numbers via activation of dendritic cells. Nat Med. 2006;12:1372–1379.|||Fritsche E, Schäfer C, Calles C, et al. Lightening up the UV response by identification of the arylhydrocarbon receptor as a cytoplasmatic target for ultraviolet B radiation. Proc Natl Acad Sci USA. 2007;104:8851–8856.|||Park BV, Pan F. The role of nuclear receptors in regulation of Th17/Treg biology and its implications for diseases. Cell Mol Immunol. 2015;12:533–542.|||Duarte JH, Di Meglio P, Hirota K, Ahlfors H, Stockinger B. Differential influences of the aryl hydrocarbon receptor on Th17 mediated responses in vitro and in vivo. PLoS ONE. 2013;8:e79819.|||Voo KS, Wang Y-H, Santori FR, et al. Identification of IL-17-producing FOXP3+ regulatory T-cells in humans. Proc Natl Acad Sci USA. 2009;106:4793–4798.|||Komatsu N, Okamoto K, Sawa S, et al. Pathogenic conversion of Foxp3+ T-cells into TH17 cells in autoimmune arthritis. Nat Med. 2014;20:62–68.|||Roncarolo MG, Gregori S, Battaglia M, Bacchetta R, Fleischhauer K, Levings MK. Interleukin-10-secreting type 1 regulatory T-cells in rodents and humans. Immunol Rev. 2006;212:28–50.|||Pot C, Jin H, Awasthi A, et al. Cutting edge: IL-27 induces the transcription factor c-Maf, cytokine IL-21, and the costimulatory receptor ICOS that coordinately act together to promote differentiation of IL-10-producing Tr1 cells. J Immunol. 2009;183:797–801.|||Schmitt V, Rink L, Uciechowski P. The Th17/Treg balance is disturbed during aging. Exp Gerontol. 2013;48:1379–1386.|||Scheller J, Chalaris A, Schmidt-Arras D, Rose-John S. The pro- and anti-inflammatory properties of the cytokine interleukin-6. Biochim Biophys Acta. 2011;1813:878–888.|||Jordan SC, Choi J, Kim I, et al. Interleukin 6 (IL-6) a cytokine critical to mediation of inflammation, autoimmunity and allograft rejection: therapeutic implications of IL-6 receptor blockade. Transplantation. 2017;101:32–44.|||Carpenter LL, Gawuga CE, Tyrka AR, Lee JK, Anderson GM, Price LH. Association between plasma IL-6 response to acute stress and early-life adversity in healthy adults. Neuropsychopharmacology. 2010;35:2617–2623.|||Bessede A, Gargaro M, Pallotta MT, et al. Aryl hydrocarbon receptor control of a disease tolerance defence pathway. Nature. 2014;511:184–190.|||Cantó C, Menzies KJ, Auwerx J. NAD(+) metabolism and the control of energy homeostasis: a balancing act between mitochondria and the nucleus. Cell Metab. 2015;22:31–53.|||Harden A, Young WJ. The alcoholic ferment of yeast-juice. P Roy Soc B: Biol Sci. 1906;77:405–420.|||Essa MM, Subash S, Braidy N, et al. Role of NAD+, oxidative stress, and tryptophan metabolism in autism spectrum disorders. Int J Tryptophan Res. 2013:15–14.|||Ying W. NAD+ and NADH in ischemic brain injury. Front Biosci. 2008;13:1141–1151.|||Bruzzone S, Fruscione F, Morando S, et al. Catastrophic NAD+ depletion in activated T lymphocytes through Nampt inhibition reduces demyelination and disability in EAE. PLoS ONE. 2009;4:e7897.|||Van Gool F, Galli M, Gueydan C, et al. Intracellular NAD levels regulate tumor necrosis factor protein synthesis in a sirtuin-dependent manner. Nat Med. 2009;15:206–210.|||Braidy N, Grant R, Brew BJ, Adams S, Jayasena T, Guillemin GJ. Effects of kynurenine pathway metabolites on intracellular NAD synthesis and cell death in human primary astrocytes and neurons. Int J Tryptophan Res. 2009;2:61–69.|||Kurnasov O, Goral V, Colabroy K, et al. NAD biosynthesis: identification of the tryptophan to quinolinate pathway in bacteria. Chem Biol. 2002;10:1195–1204.|||Houtkooper RH, Cantó C, Wanders RJ, Auwerx J. The secret life of NAD+: an old metabolite controlling new metabolic signaling pathways. Endocr Rev. 2010;31:194–223.|||Schwarcz R, Whetsell WO, Mangano RM. Quinolinic acid: an endogenous metabolite that produces axon-sparing lesions in rat brain. Science. 1983;219:316–318.|||Sahm F, Oezen I, Opitz CA, et al. The endogenous tryptophan metabolite and NAD+ precursor quinolinic acid confers resistance of gliomas to oxidative Stress. Cancer Res. 2013;73:3225–3234.|||Adriouch S, Haag F, Boyer O, Seman M, Koch-Nolte F. Extracellular NAD+: a danger signal hindering regulatory T-cells. Microbes Infect. 2012;14:1284–1292.|||Adriouch S, Hubert S, Pechberty S, Koch-Nolte F, Haag F, Seman M. NAD+ released during inflammation participates in T-cell homeostasis by inducing ART2-mediated death of naive T-cells in vivo. J Immunol. 2007;179:186–194.|||Bandeira LG, Bortolot BS, Cecatto MJ, Monte-Alto-Costa A, Romana-Souza B. Exogenous tryptophan promotes cutaneous wound healing of chronically stressed mice through inhibition of TNF-α and IDO activation. PLoS ONE. 2015;10:e0128439.|||Swanson KA, Zheng Y, Heidler KM, Mizobuchi T, Wilkes DS. CDIIc+ cells modulate pulmonary immune responses by production of indoleamine 2,3-di-oxygenase. Am J Resp Cell Mol. 2004;30:311–318.|||Zinkernagel RM, Doherty PC. The discovery of MHC restriction. Immunol Today. 1997;18:14–17.|||Haskins K, Kubo R, White J, Pigeon M, Kappler J, Marrack P. The major histocompatibility complex-restricted antigen receptor on T-cells. I. Isolation with a monoclonal antibody. J Exp Med. 1983;157:1149–1169.|||Exley M, Terhorst C, Wileman T. Structure, assembly and intracellular transport of the T-cell receptor for antigen. Semin Immunol. 1991;3:283–297.|||Lemos MP, Esquivel F, Scott P, Laufer TM. MHC class II expression restricted to CD8alpha+ and CD11b+ dendritic cells is sufficient for control of Leishmania major. J Exp Med. 2004;199:725–730.|||Kambayashi T, Laufer TM. Atypical MHC class II-expressing antigen-presenting cells: can anything replace a dendritic cell? Nat Rev Immunol. 2014;14:719–730.|||Iwasaki A, Medzhitov R. Control of adaptive immunity by the innate immune system. Nat Immunol. 2015;16:343–353.|||Suidan GL, Duerschmied D, Dillon GM, et al. Lack of tryptophan hydroxylase-1 in mice results in gait abnormalities. PLoS ONE. 2013;8:e59032.|||Kane MJ, Angoa-Peréz M, Briggs DI, et al. Mice genetically depleted of brain serotonin display social impairments, communication deficits and repetitive behaviors: possible relevance to autism. PLoS ONE. 2012;7:e48975.|||Abrahams BS, Geschwind DH. Advances in autism genetics: on the threshold of a new neurobiology. Nat Rev Genet. 2008;9:341–355.|||Silverman JL, Yang M, Lord C, Crawley JN. Behavioural phenotyping assays for mouse models of autism. Nat Rev Neurosci. 2010;11:490–502.|||Pardo CA, Vargas DL, Zimmerman AW. Immunity, neuroglia and neuroin-flammation in autism. Int Rev Psychiatry. 2005;17:485–495.|||Ganz ML. The lifetime distribution of the incremental societal costs of autism. Arch Pediatr Adolesc Med. 2007;161:343–349.|||Tipton LA, Blacher J. Brief report: autism awareness: views from a campus community. J Autism Dev Disord. 2014;44:477–483.|||McDougle CJ, Naylor ST, Cohen DJ, Aghajanian GK, Heninger GR, Price LH. Effects of tryptophan depletion in drug-free adults with autistic disorder. Arch Gen Psychiatry. 1996;53:993–1000.|||Leboyer M, Philippe A, Bouvard M, et al. Whole blood serotonin and plasma beta-endorphin in autistic probands and their first-degree relatives. Biol Psychiatry. 1999;45:158–163.|||Chugani DC, Muzik O, Rothermel R, et al. Altered serotonin synthesis in the dentatothalamocortical pathway in autistic boys. Ann Neurol. 1997;42:666–669.|||Chugani DC, Muzik O, Behen M, et al. Developmental changes in brain serotonin synthesis capacity in autistic and nonautistic children. Ann Neurol. 1999;45:287–295.|||Adamsen D, Ramaekers V, Ho HT, et al. Autism spectrum disorder associated with low serotonin in CSF and mutations in the SLC29A4 plasma membrane monoamine transporter (PMAT) gene. Mol Autism. 2014;5:43.|||Zimmerman AW, Jyonouchi H, Comi AM, et al. Cerebrospinal fluid and serum markers of inflammation in autism. Pediatr Neurol. 2005;33:195–201.|||Adams JB, Audhya T, McDonough-Means S, et al. Nutritional and metabolic status of children with autism vs neurotypical children, and the association with autism severity. Nutr Metab (Lond) 2011;8:34.|||Essa MM, Braidy N, Waly MI, et al. Impaired antioxidant status and reduced energy metabolism in autistic children. Res Autism Spect Dis. 2013;7:557–565.|||Kałuzna-Czaplinska J, Michalska M, Rynkowski J. Determination of tryptophan in urine of autistic and healthy children by gas chromatography/mass spectrometry. Med Sci Monit. 2010;16:CR488–CR492.|||Munn DH, Shafizadeh E, Attwood JT, Bondarev I, Pashine A, Mellor AL. Inhibition of T-cell proliferation by macrophage tryptophan catabolism. J Exp Med. 1999;189:1363–1372.|||El-Zaatari M, Chang Y-M, Zhang M, et al. Tryptophan catabolism restricts IFN-γ-expressing neutrophils and Clostridium difficile immunopathology. J Immunol. 2014;193:807–816.